BioLife Solutions/$BLFS

1D1W1MYTD1Y5YMAX

About BioLife Solutions

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Ticker
$BLFS
Sector
Health
Primary listing
NASDAQ
Employees
155
Headquarters
Bothell, United States
Website
www.biolifesolutions.com

BLFS Metrics

BasicAdvanced
$1.7B
30.46
$1.16
1.90
-

What the Analysts think about BLFS

Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.
Analyst projections of the future price of BioLife Solutions stock.

Bulls say / Bears say

Total revenue was $28.5 million in Q2 2026, up 21 % year-over-year, and six-month revenue grew 23 % to $56.0 million, with adjusted EBITDA margin rising to 26 %. (PRNewswire)
CryoStor is utilized in approximately 250 commercially sponsored clinical trials (>70 % market share) including over 30 Phase III trials (~80 % late-stage trials) and is embedded in 18 approved cell and gene therapies, with eight additional approvals anticipated within the next 12 months. (PRNewswire)
BioLife signed a multi-year supply agreement with Qkine, securing exclusive worldwide distribution rights for key cytokine and growth factor products in the CGT market and collaborating to integrate them into its proprietary CellSeal® Connect vial system, broadening its high-margin consumables portfolio. (PRNewswire)
The $1.5 billion takeover by Repligen hinges on regulatory and shareholder approvals and the realization of at least $20 million in first-year cost synergies, posing significant execution risk if integration challenges arise. (Reuters)
After divesting its evo cold-chain logistics unit for $25.5 million in October 2025, BioLife’s operations are highly concentrated in cell processing consumables, intensifying its vulnerability to product-specific disruption. (Reuters)
The $1.5 billion enterprise value equates to roughly 13× the high end of FY 26 revenue guidance, a stretched multiple compared to sector norms, heightening downside risk if growth falls short. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.

BLFS Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BLFS Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

BLFS News

AllArticlesVideos

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire2 weeks ago

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire2 months ago

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

MarketBeat2 months ago

Funds containing BLFS

AllUSDEURGBP
Funds
Fund name
Fund size
$BLFS weighting
iShares Healthcare Innovation$HEAL
$1.4B0.17%
iShares Healthcare Innovation€2B78
€1.2B0.17%
iShares Healthcare Innovation£DRDR
£1B0.17%
iShares S&P SmallCap 600$IDP6
$3.2B0.07%
iShares S&P Small Cap 600£ISP6
£2.4B0.07%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.